Analyse von morphologischen und funktionellen Parametern des Pankreas in Personen mit erhöhtem Risiko für ein familiäres Pankreaskarzinom

Fragestellung: Ziel dieser retrospektiven Studie war es, die Magnetresonanztomographie-(MRT)-Bildgebung des Pankreas zu verbessern. Zunächst sollte anhand morphometrischer Messungen die Anatomie des Pankreas über den transversalen Durchmesser der Pankreasanteile (Caput, Corpus, Cauda) in Abhängigke...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Oppel, Andrea
Beteiligte: Heverhagen, Johannes (Prof. Dr. Dr.) (BetreuerIn (Doktorarbeit))
Format: Dissertation
Sprache:Deutsch
Veröffentlicht: Philipps-Universität Marburg 2012
Radiologie
Schlagworte:
Online Zugang:PDF-Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

1. Ahlström, H., and H. B. Gehl. 1997. Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging. Acta Radiol 38:660-4.


2. Eisenberg, and R. C. Semelka. 1996. Enhancement of the normal pancreas: comparison of manganese-DPDP and gadolinium chelate. Eur Radiol 6:14-8.


3. Nicaise, N., O. Pellet, T. Metens, J. Devière, P. Braudé, J. Struyven, and C. Matos. 1998. Magnetic resonance cholangiopancreatography: interest of IV secretin administration in the evaluation of pancreatic ducts. Eur Radiol 8:16-22.


4. Lewis, M. P., S. K. Lo, P. U. Reber, A. Patel, B. Gloor, K. E. Todd, M. T. Toyama, S. Sherman, S. W. Ashley, and H. A. Reber. 2000. Endoscopic measurement of pancreatic tissue perfusion in patients with chronic pancreatitis and control patients. Gastrointest Endosc 51:195-9.


5. Ramsay, D., M. Marshall, S. Song, M. Zimmerman, S. Edmunds, I. Yusoff, G. Cullingford, D. Fletcher, and R. Mendelson. 2004. Identification and staging of pancreatic tumours using computed tomography, endoscopic ultrasound and mangafodipir trisodium- enhanced magnetic resonance imaging. Australas Radiol 48:154-61.


6. Matos. 2008. Pancreatic perfusion: noninvasive quantitative assessment with dynamic contrast-enhanced MR imaging without and with secretin stimulation in healthy volunteers--initial results. Radiology 247:115-21. 6. Bartsch, D. K., R. Kress, M. Sina-Frey, R. Grützmann, B. Gerdes, C. Pilarsky, J. W. Heise, K. M. Schulte, M. Colombo-Benkmann, C.


7. Hellerhoff, K. J., H. Helmberger, T. Rösch, M. R. Settles, T. M. Link, and E. J. Rummeny. 2002. Dynamic MR pancreatography after secretin administration: image quality and diagnostic accuracy. AJR Am J Roentgenol 179:121-9.


8. Huber, W., and R. M. Schmid. 2011. [Diagnosis and treatment of acute pancreatitis. Current recommendations]. Internist (Berl) 52:823-30, 832. 27. Kettritz, U., D. M. Warshauer, E. D. Brown, J. F. Schlund, L. B.


9. Heuck, A., S. Feuerbach, M. Reiser, and H. Anacker. 1985. [Computed tomographic morphometry of the normal pancreas in adults]. Rofo 142:519-23.


10. Kubo, S., K. Yamamoto, Y. Magata, Y. Iwasaki, N. Tamaki, Y. Yonekura, and J. Konishi. 1991. Assessment of pancreatic blood flow with positron emission tomography and oxygen-15 water. Ann Nucl Med 5:133-8. 32. Lankisch, P. G. 2007. Chronic pancreatitis. Curr Opin Gastroenterol 23:502-7.


11. Miura, F., T. Takada, H. Amano, M. Yoshida, S. Furui, and K. Takeshita. 2006. Diagnosis of pancreatic cancer. HPB (Oxford) 8:337-42.


12. Petersein, J., W. Reisinger, and B. Hamm. 2002. [Diagnostic value of secretin injections in dynamic MR pancreatography]. Rofo 174:437-43. 43. Punwani, S., A. R. Gillams, and W. R. Lees. 2003. Non-invasive quantification of pancreatic exocrine function using secretin-stimulated MRCP. Eur Radiol 13:273-6.


13. Sherman, and G. A. Lehman. 2006. Dynamic secretin-enhanced MR cholangiopancreatography. Radiographics 26:665-77.


14. Krebsregisterdaten, Z. f. 2012. Krebs in Deutschland 2007/2008. Berlin.


15. Biederer, J. 2005. [Magnetic resonance imaging: technical aspects and recent developments]. Med Klin (Munich) 100:62-72.


16. Leppek, R., O. Hoos, A. Sattler, S. Kohle, S. Azzam, I. Al Haffar, B. Keil, P. Ricken, K. J. Klose, and H. Alfke. 2004. [MR-Imaging of lower leg muscle perfusion]. Herz 29:32-46.


17. Torres, and J. S. Laméris. 2000. MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer. J Magn Reson Imaging 12:261-8.


18. Püspök. 2006. [Pancreas. Part I: congenital changes, acute and chronic pancreatitis]. Radiologe 46:321-35; quiz 336.


19. Puespoek, and P. Götzinger. 2007. Pancreatic adenocarcinoma. Eur Radiol 17:638-49.


20. Büchler, M. W. 2004. Pankreaserkrankungen: Akute Pankreatitis, chonische Pankreatitis, Tumore des Pankreas, vol. 2. Karger, Basel. DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience. Radiology 186:795-8.


21. Schlaudraff, E., H. J. Wagner, K. J. Klose, and J. T. Heverhagen. 2008. Prospective evaluation of the diagnostic accuracy of secretin-enhanced 63.


22. Rösch, J. 1973. Röntgendiagnostik des Pankreas und der Milz. Springer Verlag, Berlin, Heidelberg.


23. ANACKER, H. 1961. [Roentgen anatomy of the pancreas]. Fortschr Geb Rontgenstr Nuklearmed 94:1-13.


24. Gong, J., J. Xu, K. Zhou, and K. Shen. 2002. Role of exocrine cells in pancreatic enhancement using Mn-DPDP-enhanced MR imaging. Chin Med J (Engl) 115:1363-6.


25. Koopmann, J., C. N. Rosenzweig, Z. Zhang, M. I. Canto, D. A. Brown, M. Hunter, C. Yeo, D. W. Chan, S. N. Breit, and M. Goggins. 2006. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12:442-6.


26. HOLTON, P., and M. JONES. 1960. Some observations on changes in the blood content of the cat's pancreas during activity. J Physiol 150:479- 88.


27. Magnevist ®, G. Stand der Information: August 2007. Magnevist ® 0,5 mmol/ml, Injektionslösung Wirkstoff: Gadopentetat-Dimeglumin. Bayer Schering Pharma AG, Berlin. 38.


28. Lüttges, J. 2011. [What's new? The 2010 WHO classification for tumours of the pancreas]. Pathologe 32 Suppl 2:332-6.


29. A. Rizza, and P. C. Butler. 2007. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat 20:933-42.


30. Schleicher, H. Witzigmann, O. Pridöhl, M. B. Ghadimi, O. Horstmann, W. von Bernstorff, L. Jochimsen, J. Schmidt, S. Eisold, L. Estévéz-Schwarz, S. A. Hahn, K. Schulmann, W. Böck, T. M. Gress, N. Zügel, K. Breitschaft, K. Prenzel, H. Messmann, E. Endlicher, M. Schneider, A. Ziegler, W. Schmiegel, H. Schäfer, M. Rothmund, and H. Rieder. 2004. Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110:902-6.


31. Gehl, H. B., D. Vorwerk, K. C. Klose, and R. W. Günther. 1991. Pancreatic enhancement after low-dose infusion of Mn-DPDP. Radiology 180:337-9.


32. Mirowitz, S. A., E. Gutierrez, J. K. Lee, J. J. Brown, and J. P. Heiken. 1991. Normal abdominal enhancement patterns with dynamic gadolinium-enhanced MR imaging. Radiology 180:637-40.


33. Matos, C., T. Metens, J. Devière, N. Nicaise, P. Braudé, G. Van Yperen, M. Cremer, and J. Struyven. 1997. Pancreatic duct: morphologic and functional evaluation with dynamic MR pancreatography after secretin stimulation. Radiology 203:435-41.


34. Zilles, K. 2010. Anatomie. Springer Medizin Verlag, Heidelberg.


35. Fujii, and K. Sugimura. 2006. ADC measurement of abdominal organs and lesions using parallel imaging technique. AJR Am J Roentgenol 187:1521-30.


36. Kreel, L., and B. Sandin. 1973. Changes in pancreatic morphology associated with aging. Gut 14:962-70.


37. Herreros-Villanueva, M., E. Hijona, A. Cosme, and L. Bujanda. 2012. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 18:1565-72.